$pepg 5mg/kg multidose myotonic dystrophy data at start of the year? $dyn $rna

Let's see if $lly finances a $abvx-type acquisition with stock. CEO had said in that podcast that their stock was overvalued 2-3x compared to peers and Co recently said they'd be aggressively buying. Add the 2 together, it would make sense for them to take advantage of high

$abvx Matthieu Protard, the French journalist, seems to be legit with a strong track record in breaking M&A stories. Ready to risk my kids' inheritance (though not 60% like the GOAT). In biotech you need to take the shots.

$abvx you have already be substantially long the stock, would you add more here on newspaper report?

$abvx IF #miRNA124 upregulation in immune cells is indeed the mechanism for obe, then all the main miRNA target genes become potential new candidate drug targets. Obe may have stirred up a completely new area of biology rich in targets waiting to be discovered. That's also an

$abvx IF #miRNA124 upregulation in immune cells is indeed the mechanism for obe, then all the main miRNA target genes become potential new candidate drug targets. Obe may have stirred up a completely new area of biology rich in targets waiting to be discovered. That's also an

$abvx traded up to $145 on flight logs, $135 on French newspaper report. Looks like the risk/reward much, much better here.

$abvx if there is any truth to this newspaper report, things will have to move quickly now. Hoping to get a chance to increase my portfolio weighting from 10 to 20%.

French newspaper with some breaking news this morning $abvx “US Giant Eli Lilly Courts Bercy in Move to Acquire Biotech Firm Abivax A delegation from the pharmaceutical group visited the General Directorate of the Treasury in early December. The meeting was intended to subject a

$wve $arwr as I've been diving into the biology+genetics of #obesity, there is 1 resounding concept we should keep in mind when trying to address it: similar to diabetes where there is type I (lack of insulin) and type II (insulin resistance/insensitivity)... ...in obesity

Thanks guys. Your petty fights mean that drug development for pediatric drugs is at risk of becoming less attractive...even though you both claim to support it.

$10B biotech, $bmrn, buys $fold for ~$5B.

$FOLD $BMRN to acquire $FOLD $4.8B, $14.50/share 33% premium to close $BMRN continuing to be acquisitive, after $INZY, the would-be-bought continues to be the buyer… $xbi

Dr Hung says $qure strategy is to first see whether Huntington's advocacy can change FDA stance. Only then (if no result) would they go to other regulators. Me: why does it have to be sequential?

$sgmo something does not rhyme. After being criticized that for almost 30 years they operated as a sandbox for scientists, the Fabry gene therapy gave them opportunity to become commercial. Instead, they announced intention to partner/sell asset and become a preclinical biotech

$sgmo you could almost think they are a bit desperate for another ATM tapping opportunity. Today, announces 'initiation' of rolling submission (of Fabry gene therapy) a month after announcing, less than a month after 'Acceptance of BLA Rolling Submission Request'.

$abvx new, curiously timely ulcerative colitis market report supports CEO interview remarks that market is expanding because of better diagnosis and...new drugs. Obe clearly highlighted. So Big Pharma better read and raise their low-ball offers based on expected penetration of

$wve $arwr interesting yard stick for Glp1 off-ramp with inhibinE RNAi when compared to Glp subQ-->oral switch. Interestingly, for wegovy (Glp1) --> orfo (Glp1), there is no weight rebound, whereas for zepbound (Glp1+GIP) --> orfo (Glp1) there is. So loss of 1 mechanism causes

$mltx according to AI, the FDA has had a near 100% record of meeting goal of turning around minutes within 30 calendar days. That would make it January 14.